Utilization of nanobiotechnology in haemodialysis: Mock-dialysis experiments on homocysteine

Nephrology Dialysis Transplantation

Volumn 23, Issue 10, 2008, Pages 3234-3239

  Stamopoulos, Dimosthenis ^a   Bouziotis, Penelope ^b   Benaki, Dimitra ^c   Kotsovassilis, Constantinos ^d   Zirogiannis, Panagiotis N ^d  

^a INSTITUTE OF MATERIALS SCIENCE   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c Institute of Biology   (Greece)

^d G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Haemodialysis; Homocysteine; Magnetic nanoparticles; Magnetically assisted haemodialysis; Mock dialysis

Indexed keywords

FERROMAGNETIC MATERIAL; HOMOCYSTEINE; NANOPARTICLE; TOXIN;

ARTICLE; BLOOD FLOW; HEMODIALYSIS; IN VITRO STUDY; MAGNETISM; MEDICAL INSTRUMENTATION; NANOBIOTECHNOLOGY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

ANIMALS; BIOTECHNOLOGY; CATTLE; CIRCULAR DICHROISM; FERRIC COMPOUNDS; HOMOCYSTEINE; HUMANS; MAGNETICS; METAL NANOPARTICLES; MICROSCOPY, ATOMIC FORCE; NANOTECHNOLOGY; RENAL DIALYSIS; SERUM ALBUMIN, BOVINE; TOXINS, BIOLOGICAL;

EID: 52449093886     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn189     Document Type: Article

References (27)

1. Vanholder R, Argilés A, Baurmeister U et al. Uremic toxicity: present state of the art. Int J Artif Organ 2001; 24: 695-725
2. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
3. Vanholder R, De Smet R, Glorieux G et al. Survival of hemodialysis patients and uremic toxin removal. Artif Organs 2003; 27: 218-223
4. Suliman M, Stenvinkel P, Qureshi AR et al. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007; 22: 209-217
5. Refsum H, Smith AD, Ueland PM et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004; 50: 3-32
6. Suliman ME, Bárány P, Kalantar-Zadeh K et al. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005; 20: 16-21
7. Pizzolo F, Friso S, Olivieri O et al. Homocysteine, traditional risk factors and impaired renal function in coronary artery disease. Eur J Clin Inv 2006; 36: 698-704
8. Ducloux D, Klein A, Kazory A. Impact of malnutrition inflammation on the association between homocysteine and mortality. Kidney Int 2006; 69: 331-335
9. 2- microglobulin. Biochem Biophys Res Commun 1985; 129: 701-706
10. Gorevic PD, Casey TT, Stone WJ. Beta-2 microglobulin is an amyloidogenic protein in man. J Clin Invest 1985; 76: 2425-2429
11. Drüeke TB. Dialysis-related amyloidosis. Nephrol Dial Transplant 1998; 13: 58-64
12. Ronco C, Nissenson AR. Does nanotechnology apply to dialysis?. Blood Purif 2001; 19: 347-352
13. Bowry SK. Nano-controlled membrane spinning technology: regulation of pore size, distribution and morphology of a new polysulfone dialysis membrane. Contrib Nephrol Basel, Karger 2002; 137: 85-94
14. Humes HD, Fissell WH, Tiranathanagul K. The future of hemodialysis membranes. Kidney Int 2006; 69: 1115-1119
15. Fissell WH, Humes HD, Fleischman AJ et al. Dialysis and nanotechnology: now, 10 years, or never?. Blood Purif 2007; 25: 12-17
16. Stamopoulos D, Benaki D, Bouziotis P et al. In vitro utilization of ferromagnetic nanoparticles in hemodialysis therapy. Nanotechnology 2007; 18: 495102
17. Huh Y-M, Jun Y-W, Song H-T et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc 2005; 127: 12387-12391
18. Chen J, Wu H, Han D et al. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Letters 2006; 231: 169-175
19. Mornet S, Vasseur S, Grasset F et al. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem 2004; 14: 2161-2175
20. Berry CC, Curtis ASG. Functionalization of magnetic nanoparticles for applications in biomedicine. J Phys D: Appl Phys 2003; 36: R198-R206
21. Shipchandler MT, Moore EG. Rapid, fully automated measurements of plasma homocyst(e)ine with the abbott IMxR® analyzer. Clin Chem 1995; 41: 991-994
22. Pernet P, Lasnier E, Vaubourdolle M. Evaluation of the AxSYM homocysteine assay and comparison with the IMx homocysteine assay. Clin Chem 2000; 46: 1440-1441
23. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3: 1646-1654
24. Mallamaci F, Zoccali C, Triperi G. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-614
25. van Guldener, C. Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrol Dial Transplant 2006; 21: 1161-1166
26. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15: S93-S98
27. NKF-K/DOQI. Clinical Practice Guidelines for the Treatment of Anaemia of Chronic Renal Failure. New York: National Kidney Foundation, 2000